{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:54:27Z","timestamp":1794639267171,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi-Genzyme, Takeda"},{"name":"Employment\/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium"},{"DOI":"10.13039\/501100006680","name":"Takeda Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BeiGene, MSD Stemline"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"allogene, Cerus, incyte, IQVIA, Noscendo, Pentixapharm,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18\u201375 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x\u00a0ABVD followed by PET\/CT [PET-2] and 20\u00a0Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS]\u2009&lt;\u20093). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At\u00a0a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009328) and 86.7% after ABVD alone (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009300; HR\u2009=\u20092.05 [1.20\u20133.51];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0072). 5-year OS was 98.3% and 98.8%, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.14); 4\/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009353; 94.0%) than in PET-2-positive patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009340; 90.3%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012). The difference was more pronounced when using DS4 as cut-off (DS\u00a01-3:\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009571; 94.0% vs. DS\u2009\u2265\u20094:\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009122; 83.6%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-02064-y","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:02:06Z","timestamp":1697468526000},"page":"160-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma"],"prefix":"10.1038","volume":"38","author":[{"given":"Michael","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-0826","authenticated-orcid":false,"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Kuhnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Soekler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich Bernd","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-2096","authenticated-orcid":false,"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Buehnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-3514","authenticated-orcid":false,"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2064_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2005.04.4396","volume":"24","author":"J Yahalom","year":"2006","unstructured":"Yahalom J. Don\u2019t throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin\u2019s lymphoma. J Clin Oncol. 2006;24:544\u20138.","journal-title":"J Clin Oncol"},{"key":"2064_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","volume":"79","author":"T Girinsky","year":"2006","unstructured":"Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270\u20137.","journal-title":"Radiother Oncol"},{"key":"2064_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2005.02.9850","volume":"24","author":"BF Koontz","year":"2006","unstructured":"Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz R, Gockerman J, Moore J, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin\u2019s disease: cure balanced against complications. J Clin Oncol. 2006;24:605\u201311.","journal-title":"J Clin Oncol"},{"key":"2064_CR4","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, Zijlstra J, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favorable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomized, non-inferiority trial. Lancet. 2015;385:1418\u201327.","journal-title":"Lancet."},{"key":"2064_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","volume":"35","author":"S Sasse","year":"2017","unstructured":"Sasse S, Brockelmann PJ, Goergen H, Pluetschow A, Mueller H, Kreissl S, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017;35:1999\u20132007.","journal-title":"J Clin Oncol"},{"key":"2064_CR6","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","volume":"131","author":"PJ Brockelmann","year":"2018","unstructured":"Brockelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 2018;131:1666\u201378.","journal-title":"Blood"},{"key":"2064_CR7","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","volume":"23","author":"JM Connors","year":"2005","unstructured":"Connors JM. State-of-the-art therapeutics: Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:6400\u20138.","journal-title":"J Clin Oncol"},{"key":"2064_CR8","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","volume":"23","author":"RM Meyer","year":"2005","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey R, Bezjak A, Wells W, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634\u201342.","journal-title":"J Clin Oncol"},{"key":"2064_CR9","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1200\/JCO.2005.01.911","volume":"23","author":"GP Canellos","year":"2005","unstructured":"Canellos GP. Chemotherapy alone for early Hodgkin\u2019s lymphoma: an emerging option. J Clin Oncol. 2005;23:4574\u20136.","journal-title":"J Clin Oncol"},{"key":"2064_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT, Lohri A, Doerken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N. Engl J Med. 2010;363:640\u201352.","journal-title":"N. Engl J Med"},{"key":"2064_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N. Engl J Med. 2015;372:1598\u2013607.","journal-title":"N. Engl J Med"},{"key":"2064_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","volume":"32","author":"JM Raemaekers","year":"2014","unstructured":"Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2014;32:1188\u201394.","journal-title":"J Clin Oncol"},{"key":"2064_CR13","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37:2835\u201345.","journal-title":"J Clin Oncol"},{"key":"2064_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-Scan in lymphoma. Leuk Lymphoma. 2009;50:1257\u201360. https:\/\/doi.org\/10.1080\/10428190903040048.","journal-title":"Leuk Lymphoma"},{"key":"2064_CR15","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","volume":"8","author":"M Oertel","year":"2023","unstructured":"Oertel M, Hering D, Nacke N, Kittel C, Kroeger K, Kriz J, et al. Radiation therapy in the German Hodgkin Study Group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era. Adv Radiat Oncol. 2023;8:101169.","journal-title":"Adv Radiat Oncol"},{"key":"2064_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09758-z","volume":"22","author":"L van Heek","year":"2022","unstructured":"van Heek L, Stuka C, Kaul H, Mueller H, Mettler J, Hitz F, et al. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin lymphoma\u2014data from the prospective, multicenter phase III HD16 trial. BMC Cancer. 2022;22:672.","journal-title":"BMC Cancer"},{"key":"2064_CR17","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00277-022-04949-x","volume":"101","author":"M Maco","year":"2022","unstructured":"Maco M, Kupcova K, Herman V, Ondeckova I, Kozak T, Mocikova H, et al. Circulating tumor DNA in Hodgkin lymphoma. Ann Hematol. 2022;101:2393\u2013403.","journal-title":"Ann Hematol"},{"key":"2064_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andre","year":"2017","unstructured":"Andre MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35:1786\u201394.","journal-title":"J Clin Oncol"},{"key":"2064_CR19","doi-asserted-by":"crossref","unstructured":"Aurer I, Neven A, Fiaccadori V, Counsell N, Phillips E, Clifton-Hadley L, et al. Relapses in interim pet negative limited stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy\u2013analysis of EORTC\/FIL\/LYSA H10 and UK NCRI rapid trials. Hematol Oncol. 2021;39:abstr. 71.","DOI":"10.1002\/hon.71_2879"},{"key":"2064_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","volume":"33","author":"AJ Olszewski","year":"2015","unstructured":"Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33:625\u201333.","journal-title":"J Clin Oncol"},{"key":"2064_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF01738475","volume":"66","author":"N Schmitz","year":"1993","unstructured":"Schmitz N, Glass B, Dreger P, Haferlach T, Horst HA, Ollech-Chwoyka J, et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin\u2019s disease. Ann Hematol. 1993;66:251\u20136.","journal-title":"Ann Hematol"},{"key":"2064_CR22","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, Muller H, Borchmann P, Baars J, Metzner B, Doehner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol. 2010;28:5074\u201380.","journal-title":"J Clin Oncol"},{"key":"2064_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","volume":"35","author":"PJ Brockelmann","year":"2017","unstructured":"Brockelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, et al. Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials. J Clin Oncol. 2017;35:1444\u201350.","journal-title":"J Clin Oncol"},{"key":"2064_CR24","first-page":"1","volume":"3","author":"S Kreissl","year":"2018","unstructured":"Kreissl S, Goergen H, Muller H, Meissner J, Mehnert A, Buerkle C, et al. Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group. Leuk Lymphoma. 2018;3:1\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2064_CR25","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Buhnen I, Baues C, Kobe C, Kaul H, Greil R, et al. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies. Blood. 2023;142:553\u201360.","DOI":"10.1182\/blood.2023019939"},{"key":"2064_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ijrobp.2021.07.1697","volume":"111","author":"C Baues","year":"2021","unstructured":"Baues C, Goergen H, Fuchs M, Rosenbrock J, Celik E, Eich HT, et al. Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial. Int J Radiat Oncol Biol Phys. 2021;111:900\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02064-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02064-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02064-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:02:31Z","timestamp":1704790951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02064-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2064"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02064-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MF: Employment\/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium (Celgene, BMS, Takeda, Affimed, Lukon, Janssen). ASJ: No personal disclosures. HK: No personal disclosures. CK: No personal disclosures. TP: No personal disclosures. PJB: Personal disclosures regarding consulting (BeiGene, Takeda), honorarium (BeiGene, BMS, MSD Stemline, Takeda), financing of scientific studies (BeiGene, BMS, MSD, Takeda), other financial relations (Celgene (travel)). MS: No personal disclosures. MV: No personal disclosures. UD: Personal disclosures regarding honorarium (Amgen, Avencell (DSMB activities)). JM: Personal disclosures regarding consulting (MSD) and other financial relations (Travel support Takeda, MSD, BMS). CB: No personal disclosures. VD: No personal disclosures. AR: No personal disclosures. BvT: Personal disclosures regarding consulting (Allogene, BMS\/Celgene, Cerus, Incyte, IQVIA, Gilead Kite, Miltenyi, Novartis, Noscendo, Pentixapharm, Roche, Amgen, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite), honorarium (AstraZeneca, BMS, Incyte, Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme), financing of scientific studies (Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst)) and other financial relations (Travel support and congress fees: AbbVie, AstraZeneca, Gilead Kite, Merck Sharp & Dohme, Roche, Takeda, and Novartis). MD: No personal disclosures. DAE: Personal disclosures regarding honorarium (Sanofi-Genzyme, Takeda).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}